Cost-effectiveness of the tandem t: Slim X2 with control-IQ technology automated insulin delivery system in children and adolescents with type 1 diabetes in Sweden

IF 3.2 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Diabetic Medicine Pub Date : 2024-09-06 DOI:10.1111/dme.15432

Peter Adolfsson, Alina Heringhaus, Karin Sjunnesson, Laila Mehkri, Kristian Bolin

{"title":"Cost-effectiveness of the tandem t: Slim X2 with control-IQ technology automated insulin delivery system in children and adolescents with type 1 diabetes in Sweden","authors":"Peter Adolfsson, Alina Heringhaus, Karin Sjunnesson, Laila Mehkri, Kristian Bolin","doi":"10.1111/dme.15432","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>The present analysis estimated the cost-effectiveness of treatment with the Tandem t: slim X2 insulin pump with Control IQ technology (CIQ) in children with type 1 diabetes in Sweden.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A four-state Markov model and probabilistic sensitivity analyses (PSA) were used to assess the cost-effectiveness of CIQ use compared with treatment with multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII) in conjunction with CGM. Data sources included clinical input data from a recent retrospective, observational study, cost data from local diabetes supply companies and government agencies, and published literature. Outcomes measures were quality adjusted life years (QALYs) at 10, 20 and 30-year time horizons based on cost per QALY and incremental cost-effectiveness ratio (ICER).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 84 type 1 diabetes children were included (CIQ, <i>n</i> = 37; MDI, <i>n</i> = 19; CSII, <i>n</i> = 28). For all time horizons, the use of CIQ was a dominant strategy (e.g. more effective and less costly) compared with MDI or CSII use: 10-year ICER, SEK -88,010.37 and SEK -91,723.92; 20-year ICER, SEK −72,095.33 and SEK −87,707.79; and 30-year ICER, SEK −65,573.01 and SEK -85,495.68, respectively. PSA confirmed that CIQ use was less costly compared with MDI and CSII.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Initiation of CIQ use in children with type 1 diabetes is cost-saving, besides previously shown improved glycaemic control, and increased quality of life. Further investigations are needed to more fully elucidate the cost-effectiveness of these technologies in different countries with existing differences in payment models.</p>\n </section>\n </div>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":"41 11","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.15432","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetic Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dme.15432","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

The present analysis estimated the cost-effectiveness of treatment with the Tandem t: slim X2 insulin pump with Control IQ technology (CIQ) in children with type 1 diabetes in Sweden.

Methods

A four-state Markov model and probabilistic sensitivity analyses (PSA) were used to assess the cost-effectiveness of CIQ use compared with treatment with multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII) in conjunction with CGM. Data sources included clinical input data from a recent retrospective, observational study, cost data from local diabetes supply companies and government agencies, and published literature. Outcomes measures were quality adjusted life years (QALYs) at 10, 20 and 30-year time horizons based on cost per QALY and incremental cost-effectiveness ratio (ICER).

Results

A total of 84 type 1 diabetes children were included (CIQ, n = 37; MDI, n = 19; CSII, n = 28). For all time horizons, the use of CIQ was a dominant strategy (e.g. more effective and less costly) compared with MDI or CSII use: 10-year ICER, SEK -88,010.37 and SEK -91,723.92; 20-year ICER, SEK −72,095.33 and SEK −87,707.79; and 30-year ICER, SEK −65,573.01 and SEK -85,495.68, respectively. PSA confirmed that CIQ use was less costly compared with MDI and CSII.

Conclusions

Initiation of CIQ use in children with type 1 diabetes is cost-saving, besides previously shown improved glycaemic control, and increased quality of life. Further investigations are needed to more fully elucidate the cost-effectiveness of these technologies in different countries with existing differences in payment models.

Abstract Image

查看原文本刊更多论文

瑞典 1 型糖尿病儿童和青少年使用串联 t：采用 control-IQ 技术的 Slim X2 胰岛素自动给药系统对瑞典 1 型糖尿病儿童和青少年患者的成本效益。

目的：本分析估计了瑞典1型糖尿病儿童使用带Control IQ技术（CIQ）的Tandem t: slim X2胰岛素泵治疗的成本效益：方法：采用四态马尔可夫模型和概率敏感性分析 (PSA) 评估使用 CIQ 与每日多次胰岛素注射 (MDI) 或连续皮下胰岛素输注 (CSII) 结合 CGM 治疗相比的成本效益。数据来源包括近期一项回顾性观察研究的临床输入数据、当地糖尿病供应公司和政府机构提供的成本数据以及已发表的文献。研究结果以每质量调整生命年（QALY）的成本和增量成本效益比（ICER）为基础，衡量10年、20年和30年时间跨度内的质量调整生命年（QALY）：共纳入 84 名 1 型糖尿病儿童（CIQ，37 人；MDI，19 人；CSII，28 人）。在所有时间范围内，与使用 MDI 或 CSII 相比，使用 CIQ 是一种主要策略（例如，更有效且成本更低）：10年的ICER分别为-88,010.37瑞典克朗和-91,723.92瑞典克朗；20年的ICER分别为-72,095.33瑞典克朗和-87,707.79瑞典克朗；30年的ICER分别为-65,573.01瑞典克朗和-85,495.68瑞典克朗。PSA 证实，与 MDI 和 CSII 相比，使用 CIQ 的成本更低：结论：在 1 型糖尿病患儿中开始使用 CIQ 可节约成本，此外，之前的研究也表明 CIQ 可改善血糖控制并提高生活质量。需要进一步调查，以更全面地阐明这些技术在不同国家的成本效益，因为不同国家的支付模式存在差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetic Medicine 医学-内分泌学与代谢

CiteScore

7.20

自引率

5.70%

发文量

229

审稿时长

3-6 weeks

期刊介绍： Diabetic Medicine, the official journal of Diabetes UK, is published monthly simultaneously, in print and online editions. The journal publishes a range of key information on all clinical aspects of diabetes mellitus, ranging from human genetic studies through clinical physiology and trials to diabetes epidemiology. We do not publish original animal or cell culture studies unless they are part of a study of clinical diabetes involving humans. Categories of publication include research articles, reviews, editorials, commentaries, and correspondence. All material is peer-reviewed. We aim to disseminate knowledge about diabetes research with the goal of improving the management of people with diabetes. The journal therefore seeks to provide a forum for the exchange of ideas between clinicians and researchers worldwide. Topics covered are of importance to all healthcare professionals working with people with diabetes, whether in primary care or specialist services. Surplus generated from the sale of Diabetic Medicine is used by Diabetes UK to know diabetes better and fight diabetes more effectively on behalf of all people affected by and at risk of diabetes as well as their families and carers.”